The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated. We aimed to assess the effect of HIPEC after primary debulking surgery (PDS) in AOC according to patient's Breast Cancer Gene (BRCA) mutational status.
Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference? / Ghirardi, Valentina; De Felice, Francesca; D'Indinosante, Marco; Bernardini, Federica; Giudice, Maria Teresa; Fagotti, Anna; Scambia, Giovanni. - In: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. - ISSN 2468-2942. - 31:(2022). [10.1016/j.ctarc.2022.100518]
Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference?
De Felice, FrancescaSecondo
;
2022
Abstract
The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated. We aimed to assess the effect of HIPEC after primary debulking surgery (PDS) in AOC according to patient's Breast Cancer Gene (BRCA) mutational status.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ghirardi_Hyperthermic_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
977.35 kB
Formato
Adobe PDF
|
977.35 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
